Drug Trial Radar · NCT05178342
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
Last checked: Nov 20, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
38
Actual
Start
Jan 1, 2022
Primary completion
Jul 31, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- University of LeipzigAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Curis, Inc.
- First posted
- Jan 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Anemia in LR-MDS patients
Conditions
- Myelodysplastic Syndromes
- Anemia
Interventions
CA-4948Drug
Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off. Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Erythroid response (HI-E)Time frame: At the end of cycle 4 (each cycle is 28 days).
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Charité Berlin - Campus Benjamin Franklin, Med. Klinik m. S. Hämatologie, Onkologie, Tumorimmunologie
Berlin, Germany
Carl-Thiem-Klinikum Cottbus gGmbH, 2. Med. Klinik
Cottbus, Germany
Gemeinschaftspraxis Dr. Jacobasch Dresden, Hämatologie Onkologie
Dresden, Germany
Marienhospital Düsseldorf, Klinik für Onkologie und Hämatologie, Palliativmedizin
Düsseldorf, Germany
ONCOSEARCH, Institut für Klinische Studien GbR
Erlangen, Germany
InVO-Institut für Versorgungsforschung in der Onkologie
Koblenz, Germany
VK & K Studien GbR, Studienzentrum
Landshut, Germany
University Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, Hämostaseologie
Leipzig, Germany
Universitätsklinikum Schleswig-Holstein, Klinik für Hämatologie und Onkologie Campus Lübeck
Lübeck, Germany
Universitätsklinikum Mainz, III. Medizinische Klinik und Poliklinik - Hämatologie, Internistische Onkologie und Pneumologie
Mainz, Germany
Universitätsklinikum Mannheim, III. Medizinische Klinik - Hämatologie und Onkologie
Mannheim, Germany
Klinikum Hochsauerland GmbH, Klinik f. Hämatologie, Onkologie, Palliativmedizin, Stammzelltransplantation
Meschede, Germany
Klinikum rechts der Isar der TU München III. Medizinische Klinik - Hämatologie und Onkologie
München, Germany
Friedrich-Ebert-Krankenhaus GmbH, Klinik für Hämatologie, Onkologie und Nephrologie
Neumünster, Germany
Rems-Murr-Kliniken gGmbH, Hämatologie, Onkologie und Palliativmedizin
Winnenden, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.